{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:09:21Z","timestamp":1761919761168},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,10,9]],"date-time":"2013-10-09T00:00:00Z","timestamp":1381276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s11096-013-9857-x","type":"journal-article","created":{"date-parts":[[2013,10,8]],"date-time":"2013-10-08T07:41:02Z","timestamp":1381218062000},"page":"1229-1235","source":"Crossref","is-referenced-by-count":12,"title":["Treatment of multiple sclerosis in Germany: an analysis based on claims data of more than 30,000 patients"],"prefix":"10.1007","volume":"35","author":[{"given":"Roland","family":"Windt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Glaeske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falk","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,9]]},"reference":[{"issue":"7","key":"9857_CR1","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1468-1331.2006.01342.x","volume":"13","author":"M Pugliatti","year":"2006","unstructured":"Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13(7):700\u201322.","journal-title":"Eur J Neurol"},{"issue":"Suppl 2","key":"9857_CR2","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1007\/s10198-006-0384-8","volume":"7","author":"G Kobelt","year":"2006","unstructured":"Kobelt G, Berg J, Lindgren P, Elias WG, Flachenecker P, Freidel M, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ. 2006;7(Suppl 2):S34\u201344.","journal-title":"Eur J Health Econ."},{"issue":"8","key":"9857_CR3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1177\/1352458507077941","volume":"13","author":"P Sobocki","year":"2007","unstructured":"Sobocki P, Pugliatti M, Lauer K, Kobelt G. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Scler. 2007;13(8):1054\u201364.","journal-title":"Mult Scler."},{"issue":"1","key":"9857_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1474-4422(11)70268-X","volume":"11","author":"R Gold","year":"2012","unstructured":"Gold R, Montalban X. Multiple sclerosis: more pieces of the immunological puzzle. Lancet Neurol. 2012;11(1):9\u201310.","journal-title":"Lancet Neurol."},{"issue":"4","key":"9857_CR5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.clinthera.2006.04.005","volume":"28","author":"HJ Crayton","year":"2006","unstructured":"Crayton HJ, Rossman HS. Managing the symptoms of multiple sclerosis: a multimodal approach. Clin Ther. 2006;28(4):445\u201360.","journal-title":"Clin Ther"},{"issue":"13","key":"9857_CR6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","volume":"343","author":"JH Noseworthy","year":"2000","unstructured":"Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938\u201352.","journal-title":"N Engl J Med"},{"issue":"7","key":"9857_CR7","first-page":"113","volume":"105","author":"P Flachenecker","year":"2008","unstructured":"Flachenecker P, Stuke K, Elias W, Freidel M, Haas J, Pitschnau-Michel D, et al. Multiple sclerosis registry in Germany: results of the extension phase 2005\/2006. Dtsch Arztebl Int. 2008;105(7):113\u20139.","journal-title":"Dtsch Arztebl Int."},{"issue":"Pt 1","key":"9857_CR8","first-page":"133","volume":"112","author":"BG Weinshenker","year":"1989","unstructured":"Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study I. Clin Course Disabil. Brain. 1989;112(Pt 1):133\u201346.","journal-title":"Clin Course Disabil. Brain."},{"issue":"10","key":"9857_CR9","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2165\/00023210-200418100-00003","volume":"18","author":"G Giovannoni","year":"2004","unstructured":"Giovannoni G. Management of secondary-progressive multiple sclerosis. CNS Drugs. 2004;18(10):653\u201369.","journal-title":"CNS Drugs."},{"issue":"9 Suppl A","key":"9857_CR10","first-page":"S2","volume":"15","author":"RJ Lipsy","year":"2009","unstructured":"Lipsy RJ, Schapiro RT, Prostko CR. Current and future directions in MS management: key considerations for managed care pharmacists. J Manag Care Pharm. 2009;15(9 Suppl A):S2\u201315.","journal-title":"J Manag Care Pharm."},{"issue":"2","key":"9857_CR11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000095699","volume":"56","author":"T Henze","year":"2006","unstructured":"Henze T, Rieckmann P, Toyka KV. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006;56(2):78\u2013105.","journal-title":"Eur Neurol"},{"issue":"10","key":"9857_CR12","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00415-008-0061-1","volume":"255","author":"H Wiendl","year":"2008","unstructured":"Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008;255(10):1449\u201363.","journal-title":"J Neurol"},{"issue":"17","key":"9857_CR13","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1055\/s-0032-1304927","volume":"137","author":"J Havla","year":"2012","unstructured":"Havla J, Kumpfel T, Hohlfeld R. Aktuelle Diagnostik und Therapie der Multiplen Sklerose. Dtsch Med Wochenschr. 2012;137(17):894\u20139.","journal-title":"Dtsch Med Wochenschr"},{"key":"9857_CR14","unstructured":"DGN. Diagnosis and treatment of multiple sclerosis (in German). Available from: http:\/\/www.dgn.org\/component\/content\/article\/45-leitlinien-der-dgn-2012\/2333-ll-31-2012-diagnose-und-therapie-der-multiplen-sklerose.html . Accessed 21 June 2013."},{"issue":"12","key":"9857_CR15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1468-1331.2005.01352.x","volume":"12","author":"F Sellebjerg","year":"2005","unstructured":"Sellebjerg F, Barnes D, Filippini G, Midgard R, Montalban X, Rieckmann P, et al. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol. 2005;12(12):939\u201346.","journal-title":"Eur J Neurol"},{"issue":"8","key":"9857_CR16","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1468-1331.2010.03313.x","volume":"18","author":"M M\u00e4urer","year":"2011","unstructured":"M\u00e4urer M, Dachsel R, Domke S, Ries S, Reifschneider G, Friedrich A, et al. Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS. Eur J Neurol. 2011;18(8):1036\u201345.","journal-title":"Eur J Neurol"},{"issue":"2","key":"9857_CR17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00115-012-3683-6","volume":"84","author":"F Wild","year":"2013","unstructured":"Wild F. [Pharmaceutical prescription for multiple sclerosis : evaluation of pharmaceutical consumption at private health insurance.] (in German). Nervenarzt. 2013;84(2):202\u20138.","journal-title":"Nervenarzt."},{"key":"9857_CR18","unstructured":"WHO. Guidelines for ATC classification and DDD assignment 2012. Oslo 2011."},{"issue":"1","key":"9857_CR19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/BF02190090","volume":"240","author":"L Kappos","year":"1990","unstructured":"Kappos L, Heun R, Mertens HG. A 10-year matched-pairs study comparing azathioprine and no immunosuppression in multiple sclerosis. Eur Arch Psychiatry Clin Neurosci. 1990;240(1):34\u20138.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"9857_CR20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1471-2377-11-122","volume":"11","author":"JM Margolis","year":"2011","unstructured":"Margolis JM, Fowler R, Johnson BH, Kassed CA, Kahler K. Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. BMC Neurol. 2011;11:122.","journal-title":"BMC Neurol."},{"issue":"10","key":"9857_CR21","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","volume":"7","author":"DD Mikol","year":"2008","unstructured":"Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903\u201314.","journal-title":"Lancet Neurol."},{"issue":"10","key":"9857_CR22","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","volume":"8","author":"P O\u2019Connor","year":"2009","unstructured":"O\u2019Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 \u03bcg or 500 \u03bcg interferon beta-1b versus 20\u00a0mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889\u201397.","journal-title":"Lancet Neurol."},{"issue":"9","key":"9857_CR23","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1177\/1352458510371410","volume":"16","author":"JJ Marriott","year":"2010","unstructured":"Marriott JJ, O\u2019Connor PW. Lessons learned from long-term multiple sclerosis treatment trials. Mult Scler. 2010;16(9):1028\u201330.","journal-title":"Mult Scler."},{"key":"9857_CR24","unstructured":"Windt R. Multiple Sklerose. BARMER GEK Arzneimittelreport 2010. Germany: Asgard; 2010, ISBN 978-3943744675. pp. 124\u201336."},{"issue":"5","key":"9857_CR25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/s-0031-1275711","volume":"74","author":"F Hoffmann","year":"2012","unstructured":"Hoffmann F, Icks A. [Structural differences between health insurance funds and their impact on health services research: results from the Bertelsmann Health-Care Monitor] (in German). Gesundheitswesen. 2012;74(5):291\u20137.","journal-title":"Gesundheitswesen."},{"issue":"11","key":"9857_CR26","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1007\/s00415-009-5257-5","volume":"256","author":"K Stuke","year":"2009","unstructured":"Stuke K, Flachenecker P, Zettl UK, Elias WG, Freidel M, Haas J, et al. Symptomatology of MS: results from the German MS Registry. J Neurol. 2009;256(11):1932\u20135.","journal-title":"J Neurol"},{"issue":"1","key":"9857_CR27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/01.WNL.0000101724.93433.00","volume":"62","author":"SJ Pittock","year":"2004","unstructured":"Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH, et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology. 2004;62(1):51\u20139.","journal-title":"Neurology."},{"key":"9857_CR28","first-page":"CD006921","volume":"3","author":"JM Burton","year":"2009","unstructured":"Burton JM, O\u2019Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev. 2009;3:CD006921.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"9857_CR29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-510X(98)00116-6","volume":"160","author":"PB Andersson","year":"1998","unstructured":"Andersson PB, Goodkin DE. Glucocorticosteroid therapy for multiple sclerosis: a critical review. J Neurol Sci. 1998;160(1):16\u201325.","journal-title":"J Neurol Sci"},{"issue":"1\u20132","key":"9857_CR30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jns.2006.05.074","volume":"259","author":"C Heesen","year":"2007","unstructured":"Heesen C, Kasper J, Kopke S, Richter T, Segal J, Muhlhauser I. Informed shared decision making in multiple sclerosis\u2013inevitable or impossible? J Neurol Sci. 2007;259(1\u20132):109\u201317.","journal-title":"J Neurol Sci"},{"issue":"1","key":"9857_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2004.00284.x","volume":"110","author":"S K\u00f6pke","year":"2004","unstructured":"K\u00f6pke S, Heesen C, Kasper J, M\u00fchlhauser I. Steroid treatment for relapses in multiple sclerosis\u2014the evidence urges shared decision-making. Acta Neurol Scand. 2004;110(1):1\u20135.","journal-title":"Acta Neurol Scand"},{"key":"9857_CR32","doi-asserted-by":"crossref","unstructured":"Loikas D, Wettermark B, von Euler M, Bergman U, Schenck-Gustafsson K, et al. Differences in drug utilisation between men and women: a cross-sectional analysis of all dispensed drugs in Sweden. BMJ Open. 2013;3:e002378.","DOI":"10.1136\/bmjopen-2012-002378"},{"issue":"5","key":"9857_CR33","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1089\/jwh.2007.0731","volume":"17","author":"M Anthony","year":"2008","unstructured":"Anthony M, Lee KY, Bertram CT, Abarca J, Rehfeld RA, Malone DC, et al. Gender and age differences in medications dispensed from a national chain drugstore. J Womens Health (Larchmt). 2008;17(5):735\u201343.","journal-title":"J Womens Health (Larchmt)."},{"issue":"5","key":"9857_CR34","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s11096-011-9536-8","volume":"33","author":"K Johnell","year":"2011","unstructured":"Johnell K, Fastbom J. Gender and use of hypnotics or sedatives in old age: a nationwide register-based study. Int J Clin Pharm. 2011;33(5):788\u201393.","journal-title":"Int J Clin Pharm."},{"issue":"5","key":"9857_CR35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s15010-006-6618-y","volume":"34","author":"WV Kern","year":"2006","unstructured":"Kern WV, de With K, Nink K, Steib-Bauert M, Schroder H. Regional variation in outpatient antibiotic prescribing in Germany. Infection. 2006;34(5):269\u201373.","journal-title":"Infection"},{"issue":"1","key":"9857_CR36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijcard.2004.03.074","volume":"102","author":"J Muller-Nordhorn","year":"2005","unstructured":"Muller-Nordhorn J, Kulig M, Binting S, Voller H, Krobot KJ, Willich SN. Regional variation in medication following coronary events in Germany. Int J Cardiol. 2005;102(1):47\u201353.","journal-title":"Int J Cardiol"},{"issue":"3","key":"9857_CR37","first-page":"10","volume":"2","author":"C Bensing","year":"2009","unstructured":"Bensing C, Kleinfeld A. Medikament\u00f6se Therapie der fr\u00fchen rheumatoiden Arthritis. Monitor Versorgungsforschung. 2009;2(3):10\u20131.","journal-title":"Monitor Versorgungsforschung."},{"issue":"10","key":"9857_CR38","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s00393-011-0873-8","volume":"70","author":"R Windt","year":"2011","unstructured":"Windt R, Glaeske G, Hoffmann F. Versorgung mit TNF-alpha-Blockern und regionale Unterschiede im Jahr 2010. Z Rheumatol. 2011;70(10):874\u201381.","journal-title":"Z Rheumatol"},{"issue":"12","key":"9857_CR39","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1055\/s-0029-1214399","volume":"71","author":"A Erler","year":"2009","unstructured":"Erler A, Beyer M, Muth C, Gerlach FM, Brennecke R. [Garbage in\u2014garbage out? Validity of coded diagnoses from GP claims records] (in German). Gesundheitswesen. 2009;71(12):823\u201331.","journal-title":"Gesundheitswesen."},{"issue":"4","key":"9857_CR40","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s001150050559","volume":"71","author":"T Hein","year":"2000","unstructured":"Hein T, Hopfenmuller W. Hochrechnung der Zahl an Multiple Sklerose erkrankten Patienten in Deutschland. Nervenarzt. 2000;71(4):288\u201394.","journal-title":"Nervenarzt."},{"key":"9857_CR41","unstructured":"DIMDI (German Insitute of Medical Documentation and Information). ATC-Classification System with Defined Daily Doses. Available from: http:\/\/www.dimdi.de\/static\/en\/klassi\/atcddd\/index.htm . Accessed 27 June 2013."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-013-9857-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-013-9857-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-013-9857-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T05:54:43Z","timestamp":1559368483000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-013-9857-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,9]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["9857"],"URL":"https:\/\/doi.org\/10.1007\/s11096-013-9857-x","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,9]]}}}